{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:24:50Z","timestamp":1787750690291,"version":"build-2784847793"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    This case report describes the successful treatment of a patient with acute monocytic leukemia (AML-M5), positive for the\n                    <jats:italic toggle=\"yes\">KMT2A::AFDN<\/jats:italic>\n                    fusion gene, who relapsed and developed central nervous system involvement after allogeneic hematopoietic stem cell transplantation. The patient was a 32-year-old male initially treated with conventional chemotherapy followed by transplantation; however, he experienced relapse with AML infiltration of the CNS. Based on the MLL abnormality, salvage therapy was administered using the menin inhibitor Revumenib combined with venetoclax and azacitidine, followed by donor lymphocyte infusion (DLI). After one course of treatment, he achieved minimal residual disease (MRD)-negative status in both bone marrow and cerebrospinal fluid, with sustained complete remission. The main adverse effects observed were grade IV myelosuppression and grade II gastrointestinal symptoms. This case indicates that the salvage strategy incorporating Revumenib, venetoclax, azacitidine, and DLI not only exhibits potential for achieving deep remission in\n                    <jats:italic toggle=\"yes\">KMT2A<\/jats:italic>\n                    -rearranged AML but also aids in controlling central nervous system infiltration, thereby providing a novel therapeutic direction for patients with relapsed AML. Further studies involving larger sample sizes are required to assess the long-term survival benefits of this strategy.\n                  <\/jats:p>","DOI":"10.1177\/20406207261484015","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:57:58Z","timestamp":1787601478000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of relapsed\n                    <i>KMT2A<\/i>\n                    rearranged AML with central nervous system involvement using revumenib in combination with venetoclax and azacitidine: A case report"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4438-1506","authenticated-orcid":false,"given":"Jialiang","family":"Xu","sequence":"first","affiliation":[{"name":"School of Medicine, the Sixth Affiliated Hospital of South China University of Technology (Nanhai District People's Hospital of Foshan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangpeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine, the Sixth Affiliated Hospital of South China University of Technology (Nanhai District People's Hospital of Foshan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00376-1"},{"issue":"5","key":"e_1_3_7_3_2","first-page":"317","article-title":"Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia","volume":"13","author":"Medinger M","year":"2016","unstructured":"Medinger M, Lengerke C, Passweg J. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer genomics & proteomics 2016; 13(5): 317\u2013329.","journal-title":"Cancer genomics & proteomics"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02634-2"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03830-0"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.074"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2023.104869"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.016"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12246"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.1.224-234.2001"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/378505a0"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-465120"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002697"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1900"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00914"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029712"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00496"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010039"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S125259"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261484015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261484015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261484015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:16:47Z","timestamp":1787750207000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261484015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"alternative-id":["10.1177\/20406207261484015"],"URL":"https:\/\/doi.org\/10.1177\/20406207261484015","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20406207261484015"}}